NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 107 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.50 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3 | -62.5% | 3,100 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $8 | -33.3% | 3,100 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $12 | +20.0% | 3,100 | +47.6% | 0.00% | 0.0% |
| Q4 2022 | $10 | -99.9% | 2,100 | -30.0% | 0.00% | 0.0% |
| Q3 2022 | $19,000 | +1800.0% | 3,000 | +500.0% | 0.00% | – |
| Q2 2022 | $1,000 | -66.7% | 500 | -88.6% | 0.00% | – |
| Q1 2022 | $3,000 | -78.6% | 4,400 | -78.1% | 0.00% | -100.0% |
| Q4 2021 | $14,000 | -62.2% | 20,100 | +200.0% | 0.00% | -50.0% |
| Q3 2021 | $37,000 | +94.7% | 6,700 | +509.1% | 0.00% | +100.0% |
| Q2 2021 | $19,000 | -68.9% | 1,100 | -47.6% | 0.00% | -66.7% |
| Q1 2021 | $61,000 | +1.7% | 2,100 | +5.0% | 0.00% | 0.0% |
| Q4 2020 | $60,000 | +900.0% | 2,000 | +100.0% | 0.00% | – |
| Q3 2020 | $6,000 | -33.3% | 1,000 | -9.1% | 0.00% | – |
| Q2 2020 | $9,000 | – | 1,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |